"A US Food and Drug Administration (FDA) advisory panel has backed a new biologic for psoriasis, though the panelists recommended strong warnings about the potential for suicide and self-injurious behavior (SIB) with the drug.
Topically applied Taclonex® (calcipotriene and betamethasone dipropionate) Ointment can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS).
Taclonex® (calcipotriene and betamethasone dipropionate) Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Taclonex® (calcipotriene and betamethasone dipropionate) Ointment is contraindicated in patients with erythrodermic, exfoliative and pustular psoriasis.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/22/2016
Additional Taclonex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.